BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Aging
    • Biosimilars
    • Artificial intelligence
    • Coronavirus
    • IVDs on the rise
    • Radiopharmaceuticals
    • Science '22 in Review
    • Top Biopharma Trends of 2022
    • Top Med-tech Trends of 2022
    • Premium reports
      • BioWorld Financings Reports
      • Disease Incidence & Prevalence Summaries

BioWorld. Link to homepage.

  • sign in
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, September 22, 2023
Home » Topics » Financings

Financings
Financings RSS Feed RSS

Fore closes its series D to advance BRAF alterations drug

Aug. 23, 2023
By Lee Landenberger
No Comments
Fore Biotherapeutics Inc. has closed on a $75 million series D financing so that it can continue developing its lead asset, plixorafenib, an oral small molecule that selectively inhibits BRAF alterations.
Read More

Rapport adds $150M in series B to accelerate push into precision neuromedicine

Aug. 23, 2023
By Cormac Sheridan
No Comments
Rapport Therapeutics Inc. raised $150 million in a series B round, less than six months after unveiling its $100 million series A investment. It’s further evidence that its distinctive precision neuromedicine approach has gained traction with some deep-pocketed investors and adds further momentum both to its clinical development and its discovery research efforts.
Read More

Financings for Aug. 23, 2023

Aug. 23, 2023
No Comments
Biopharmas raising money in public or private financings, including: Janone, Sobi.
Read More

Financings for Aug. 23, 2023

Aug. 23, 2023
No Comments
Med-tech firms raising money in public or private financings, including: Shoulder Innovations.
Read More

Financings for Aug. 22, 2023

Aug. 22, 2023
No Comments
Med-tech firms raising money in public or private financings, including: Delphinus Medical.
Read More

NDA submitted, Jyong seeks up to $40M in IPO for urinary disorders

Aug. 22, 2023
By Randy Osborne
No Comments
Jyong Biotech Ltd. filed for an IPO that could raise as much as $40 million to advance a pipeline that includes several prospects for urinary system disorders, including one that has reached the NDA stage in the U.S.
Read More

Financings for Aug. 22, 2023

Aug. 22, 2023
No Comments
Biopharmas raising money in public or private financings, including: Actimed, Bird Rock, Foundery, Promis, Psyence, Skye.
Read More
Digital brain and silhouette

Brainaurora files for Hong Kong IPO to develop digital therapeutics

Aug. 22, 2023
By Doris Yu
No Comments
Brainaurora Medical Technology Ltd. has filed for an initial public offering (IPO) in Hong Kong to develop its digital therapeutics for the treatment of cognitive impairment diseases. The company claims to be the first in China to launch a digital therapeutics (DTx) product for cognitive impairment, as well as the largest company in China in terms of revenue from the commercialization of cognitive impairment DTx products in 2022.
Read More

Financings for Aug. 21, 2023

Aug. 21, 2023
No Comments
Biopharmas raising money in public or private financings, including: Abivax, Astrocyte, Genesis and Mysthera.
Read More

Financings for Aug. 18, 2023

Aug. 18, 2023
No Comments
Med-tech firms raising money in public or private financings, including:Viome Life Sciences.
Read More
Previous 1 2 … 5 6 7 8 9 10 11 12 13 … 420 421 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Sept. 22, 2023.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for September 22, 2023.
  • Hands holding torn contract

    Quite a fix: Orthofix sacks three top execs

    BioWorld MedTech
    Orthofix Medical Inc. terminated its CEO, chief financial officer and chief legal officer in a move that plunged the stock from $18.63 at Monday’s close to $13.01...
  • New NLRP3 inflammasome inhibitors named in PTC Therapeutics patent

    BioWorld Science
    PTC Therapeutics Inc. has patented new NLRP3 inflammasome inhibitors reported to be useful...
  • Illustration of Alzheimer’s in the brain.

    Study identifies cause of death for Alzheimer’s neurons

    BioWorld
    By creating a new mouse model of Alzheimer’s disease that better recapitulated how the disease plays out in humans, investigators at KU Leuven have gained new...
BioFuture ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
Follow Us

Copyright ©2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing